Is there a standard adjuvant treatment for colon cancer?: Current controversies in cancer

European Journal of Cancer

Volumn 34, Issue 11, 1998, Pages 1652-1655

  Slevin, M L ^a   Papamichael, D ^a   Rougier, P ^a   Schmoll, H J ^a  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; CARCINOEMBRYONIC ANTIGEN; CYTOKERATIN; FAS ANTIGEN; FLUOROURACIL; FOLINIC ACID; LEVAMISOLE; PROTEIN BCL 2; PROTEIN P53; THYMIDYLATE SYNTHASE; TUMOR MARKER;

CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; COLON CANCER; IMMUNOMODULATION; IMMUNOTHERAPY; NOTE; ONCOGENE K RAS; PORTAL VEIN; PRIORITY JOURNAL;

EID: 0031691779     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(98)00251-2     Document Type: Article

References (41)

1. Rousselot LM, Cole DR, Grossi CE, et al. Intraluminal chemotherapy (HN2 of 5-FU). Adjuvant to operation for cancer of the colon and rectum. Cancer 1967, 20 , 829–833.
2. Grossi CE, Wolf WI, Nealon TF, et al. Intraluminal fluorouracil chemotherapy adjuvant to surgical procedure of resectable carcinoma of the colon and rectum. Sur Gyn Obst 1977, 145 , 549.
3. Lawrence W, Terz JJ, Horsley S, et al. Chemotherapy as an adjuvant to surgery for colorectal cancer. Ann Surg 1975, 181 , 616–623.
4. Dixon WJ, Longmire WP, Holden WD. Use of triethylenethiophosphoramide as an adjuvant to the surgical treatment of gastric and colorectal carcinoma: ten year follow-up. Ann Surg 1971, 173 , 26–39.
5. The Veterans Administration Surgical Adjuvant Cancer Chemotherapy Group. Adjuvant use of HN2 (NSC-762). Progress report. Cancer Chemother Rep 1965, 44 , 27–30.
6. Higgins GA, Amadeo JH, McElhinney J, et al. Efficacy of prolonged intermittent therapy with combined 5-fluorouracil and methyl-CCNU following resection for carcinoma of the large bowel. Cancer 1984, 53 , 1–8.
7. Panettiere FJ, Goodman PJ, Costanzi JJ, et al. Adjuvant therapy in large bowel adenocarcinoma: long-term results of a Southwest Oncology Group Study. J Clin Oncol 1988, 6 , 948–954.
8. Mansour EG, McIntyre JW, Johnson R, et al. Adjuvant studies in colorectal carcinoma: experience of the Eastern Cooperative Oncology Group (ECOG). Preliminary report. In Gerard A, ed. Progress and Perspectives in the Treatments of Gastrointestinal Tumours . New York, Pergamon Press, 1981, 68–75.
9. Wolmark N, Fisher B, Rockette H, et al. Post-operative adjuvant chemotherapy or BCG for colon cancer: results from NSABP protocol C-01. J Natl Cancer Inst 1988, 80 , 30–36.
10. D. Tripodi L.C. Parks J. Brugmans Drug-induced restoration of cutaneous delayed hypersensitivity in anergic patients with cancer N Engl J Med 289 1978 354 357
11. Arnaud JP, Buyse M, Nordlinger B, et al. Adjuvant therapy of poor prognostic colon cancer with levamisole: result of an EORTC double-blind randomized clinical trial. Br J Surg 1989, 76 , 284–289.
12. Davis T, Borden E, Wolbert W, et al. Levamisole and 5-fluorouracil in metastatic colorectal carcinoma (Abstract). Proc ASCO 1982, 1 , Abstract 396.
13. Buroker T, Moertel C, Fleming T, et al. A controlled evaluation of recent approaches to biochemical modulation or enhancement of 5-fluorouracil therapy in colorectal carcinoma. J Clin Oncol 1985, 3 , 1624.
14. Mansour EG, Cnaan A, Davis T, et al. Combined modality therapy following resection of colorectal carcinoma in patients with non-measurable intra-abdominal metastases. An ECOG study 3282 (Abstract). Proc ASCO 1990, 9 , Abstract 412.
15. Moertel CG, Fleming TR, Macdonald JS, et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 1990, 332: , 352–358.
16. Anonymous. The efficacy and the group C status of levamisole and 5-fluorouracil for patients with Dukes’ C colon cancer. National Cancer Institute Update, October 1989.
17. Moertel CG, Fleming TR, Macdonald JS, et al. Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann Intern Med 1995, 122 , 321–326.
18. Advanced Colorectal Cancer Meta-analysis Project. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J Clin Oncol 1992, 10 , 896–903.
19. Wolmark N, Rockette H, Fisher B, et al. The benefit of leucovorin modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from NSABP C-03. J Clin Oncol 1993, 11 , 1879–1887.
20. Anonymous. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT). Lancet 1995, 345 (8955), 939–944.
21. Francini G, Petrioli R, Marsili S, et al. Folinic acid plus 5-fluorouracil as adjuvant chemotherapy in colon cancer. Proc ASCO 1994, 13 , Abstract 571.
22. O’Connell MJ, Mailliard JA, Kahn MJ, et al. Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. J Clin Oncol 1997, 15 , 246–250.
23. Wolmark N, Rockette H, Mamounas EP, et al. The relative efficacy of 5-FU+leucovorin (5-FU-LV), 5-FU+levamisole (LEV), and 5-FU+LV+LEV (5-FU-LV-LEV) in patients with Dukes’ B and C carcinoma of the colon: first report of NSABP C-04. Proc ASCO 1996, 14 , Abstract 460.
24. O’Connell MJ, Laurie JA, Shepherd L, et al. A prospective evaluation of chemotherapy duration and regimen as surgical adjuvant treatment for high risk colon cancer: a collaborative trial of the North Central Cancer Treatment Group and the National Cancer Institute of Canada Clinical Trials Group. Proc ASCO 1996, 14 , Abstract 478.
25. Haller DG, Catalano PJ, et al. Eastern Cooperative Oncology Group (ECOG), Southwest Oncology Group (SWOG), Cancer and Acute Leukaemia Group B (CALGB fluorouracil, leucovorin and levamisole adjuvant therapy for colon cancer: preliminary results of INT-0089. Proc ASCO 1996, 14 , Abstract 486.
26. Seymour MT, Slevin ML, Kerr DJ, et al. Randomized trial assessing the addition of interferon alpha-2a to fluorouracil and leucovorin in advanced colorectal cancer. Colorectal Cancer Working Party of the United Kingdom Medical Research Council. J Clin Oncol 1996, 14 (8), 2280–2288.
27. Hill M, Norman A, Cunningham D, et al. Royal Marsden Phase III trial of fluorouracil with or without interferon alfa-2b in advanced colorectal cancer. J Clin Oncol 1995, 13 , 1297–1302.
28. Greco FA, Figlin R, York M, et al. Phase III study to compare interferon alfa-2a in combination with fluorouracil versus fluorouracil alone in patients with advanced colorectal cancer. J Clin Oncol 1996, 14 , 2674–2681.
29. N. Anderson J.J. Lokich Cancer chemotherapy and infusional scheduling Oncology 8 1994 99 116
30. De Gramont A, Krulik M, Cady J, et al. High dose folinic acid and 5-fluorouracil bolus and continuous infusion in advanced colorectal cancer. Eur J Cancer Clin Oncol 1988, 24 , 1499–1503.
31. de Gramont A, Bosset J-F, Milan C, et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol 1997, 15 , 808–815.
32. Anonymous. Portal vein chemotherapy for colorectal cancer: a meta-analysis of 4000 patients in 10 studies. J Natl Cancer Inst 1997, 89 , 497–505.
33. Piedbois P, Buyse M, Gray R, et al. Portal vein infusion is an effective adjuvant treatment for patients with colorectal cancer. Proc ASCO 1995; 14 , Abstract 444.
34. Scheithauer W, Marczell A, Depisch D, et al. Combined intravenous and intraperitoneal chemotherapy with 5-fluorouracil (5FU) and leucovorin versus 5-FU and levamisole for adjuvant therapy of resected colon carcinoma. Proc ASCO 1996, 14 , Abstract 507.
35. Moertel CG, Fleming TR, Macdonald JS, et al. Intergroup study of fluorouracil plus levamisole as adjuvant therapy for stage II/Dukes’ B2 colon cancer. J Clin Oncol 1995, 13 (12), 2936–2943.
36. Mamounas EP, Rockette H, Jones J, et al. Comparative efficacy of adjuvant chemotherapy in patients with Dukes’B vs Dukes’ C colon cancer: results from four NSABP adjuvant studies (C-01, C-02, C-03, C-04). Proc ASCO 1996, 14 , Abstract 461.
37. Wolmark N, Fisher B, Rockette H, et al. Postoperative adjuvant chemotherapy for BCG for colon cancer: results from NSABP protocol C-01. J Natl Cancer Inst 1988, 80 , 30–36.
38. Riethmuller G, Holz E, Schlimok G, et al. Monoclonal antibody (Mab) adjuvant therapy of Dukes C colorectal carcinoma: 7-year update of a prospective randomized trial. Proc ASCO 1996, 14 , Abstract 1385.
39. Peters GJ, van der Wilt CL, van Groeningen CJ, et al. Thymidylate synthase inhibition after administration of fluorouracil with or without leucovorin in colon cancer patients: implications for treatment with fluorouracil. J Clin Oncol 1994, 12 (10), 2035–2042.
40. Johnston PG, Fisher ER, Rockette HE, et al. The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer. J Clin Oncol 1994, 12 (12), 2640–2647.
41. Zhao-Shi Zeng, Sarkis AS, Zuo-Feng Zhang, et al. p53 nuclear overexpression: an independent predictor of survival in lymph node-positive colorectal cancer patients. J Clin Oncol 1994, 12 (10), 2043–2050.